Figure out the Efficacy and Safety of Azacitidine Combined with BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome with Moderate High IPSS-M Score

This study is a prospective, single-center, single-arm clinical study, which plans to enroll 40 patients with high-risk myelodysplastic syndrome (MDS) to be given azacitidine (AZA) combined with busulfan and cyclophosphamide (BUCY2) conditioning regimen to evaluate 18-month progression-free survival (PFS), aiming to evaluate the efficacy and safety of azacitidine plus BUCY2 pretreatment regimen.

Inclusion Criteria:

• Patients fully understand this study, voluntarily participate and sign the informed consent form
• Age equal or more than 18 years old
• Patients with moderate high-risk MDS with an IPSS-M score which is higher than 0
• Patients planning to undergo allogeneic hematopoietic stem cell transplantation, HCT-CI ≤ 3 or KPS ≥ 80%

Exclusion Criteria:

• Patients who refuse to participate in this clinical study
• Patients with central nervous system involvement
• Patients with HIV seropositive
• Patients with other serious medical conditions with a life expectancy of less than six months
• Patients with severe psychiatric or psychological disorders